RecruitingPhase 2NCT06760819
Oncology
Ampullary Carcinoma
Also known as ampulla of Vater cancer, periampullary cancer, ampullary adenocarcinoma
Ampullary carcinoma is a rare malignancy arising at the ampulla of Vater, the confluence of the common bile duct and pancreatic duct at the duodenal papilla, and is classified into intestinal and pancreatobiliary subtypes based on histologi
ORPHA:67380 ↗Prevalence 0.2–0.5 in 100,000Onset Adult (median age 60s)Sporadic; FAP-associated in familial cases
17
studies recruiting now
as of 7 Sept 2026
63
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
24 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07780838
Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for the Treatment of Unresectable, Locally Advanced or Metastatic Biliary Tract Cancers With FGFR2 Alterations
RecruitingNot applicableNCT07283939
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
RecruitingNot applicableNCT05497531
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RecruitingNCT07781137
Analysis of Long-term Outcomes of Endoscopic Resection of Duodenal and Ampullary Mucosal and Submucosal Lesions
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 17 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Ampullary Carcinoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Ampullary Carcinoma
Ampullary carcinoma is a rare malignancy arising at the ampulla of Vater, the confluence of the common bile duct and pancreatic duct at the duodenal papilla, and is classified into intestinal and pancreatobiliary subtypes based on histological and immunohistochemical phenotype. The intestinal subtype shares molecular features with colorectal adenocarcinoma, including frequent KRAS and APC mutations, while the pancreatobiliary subtype resembles pancreatic ductal adenocarcinoma in biology and prognosis. Despite its rarity, ampullary carcinoma carries a relatively favourable prognosis among periampullary tumours when resected at an early stage, with five-year survival rates of 30–50% following pancreaticoduodenectomy (Whipple procedure).
Common clinical features
Obstructive jaundice: painless jaundice, dark urine, and pale stools from biliary obstruction at the ampullaIntermittent jaundice caused by tumour necrosis and temporary relief of obstruction (characteristic of ampullary location)Courvoisier sign: palpable, non-tender gallbladder from distension due to biliary obstructionPancreatitis from pancreatic duct obstruction causing epigastric pain and elevated amylase/lipaseIron-deficiency anaemia or occult gastrointestinal bleeding from duodenal mucosal erosionWeight loss, anorexia, and fatigueCholangitis: fever, rigors, and right upper quadrant pain from infected bile in cases with biliary stasis
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Ampullary Carcinoma. Not eligibility rules; those are set by each study.
- Histological subtype (intestinal vs. pancreatobiliary) is an important stratification factor in most trials; request immunohistochemical panel including CK7, CK20, CDX2, and MUC markers to establish subtype.
- MSI/MMR status and KRAS mutation status must be documented as they are eligibility and predictive biomarkers for immunotherapy and targeted therapy trials respectively.
- Surgical resection status (R0 vs. R1 resection vs. unresectable) and biliary drainage adequacy (stent patency, bilirubin normalisation) are prerequisites for most systemic therapy trials — ensure bilirubin is within protocol-specified limits before screening.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).